Article open access publication

Melanoma and immunotherapy bridge 2015

Journal of Translational Medicine, Springer Nature, ISSN 1479-5876

Volume 14, Suppl 1, 2016

DOI:10.1186/s12967-016-0791-2, Dimensions: pub.1032029057, PMC: PMC4965835, PMID: 27461275,

Authors

Ascierto, Paolo Antonio (2) (3) (6) (7) (8)
Wang, Yang (16)
Dummer, Reinhard (17) (18) (19)
Puzanov, Igor (20) (21)
Wang, Hong (23)
Kirkwood, John M. (22) (23) (24)
Maurer, Mark (23) (25)
Korman, Alan J. (23) (25)
Zarour, Hassane M (23) (25)
Pagès, Franck (29) (30)
Jommi, Claudio (33) (34)
Gentilcore, Giusy (35) (36)
Poschke, Isabel (35) (37)
Scognamiglio, Giosue' (26) (38) (39) (40)
Cantile, Monica (39) (40) (42)
Robert, Caroline (46) (47) (48)
Ribas, Antoni (51) (52)
Caro, Ivor (59)
Postow, Michael A. (15) (45)
Atkinson, Victoria (73) (74)
He, Xian (59)
Long, Georgina V (65) (87)
Chen, Lisa (95)
McNeil, Catriona (100) (101) (102)
Ny, Lars (105)
Wolchok, Jedd D. (45) (119)
Strippoli, Sabino (120) (121)
Azzariti, Amalia (120) (121)
Guida, Michele (120) (121)
Tommasi, Stefania (120) (121)
Jacquelot, Nicolas (47) (48)
Blattner, Carolin (37) (123)
Daillere, Romain (47) (48)
Weide, Benjamin (76) (128)
Kroemer, Guido (29) (30) (47) (131) (132) (133) (134)
Umansky, Viktor (37) (123)
Zitvogel, Laurence (47) (48)
Marco, Tucci (122)
Semeraro, Michaela (47) (124)
Jegou, Sarah (136)
Kwon, Byoung S. (137) (138)
Borg, Christophe (140) (141)
Ayyoub, Maha (47) (48)
Camerlingo, Rosa (2) (7) (144)
Fratangelo, Federica (2) (3) (7)
Pirozzi, Giuseppe (2) (7) (144)
Motti, Maria Letizia (3) (7) (145) (146)
Falcon, Rosaria (7) (8)
Botti, Gerardo (38) (39) (40) (42)
Sandru, Angela (66) (147)
Blank, Miri (148)
Wang, Hexiao (150)
Crook, Tim (150)
Tucci, Marco (122)
Ferretta, Anna (121) (122)
Maida, Imma (122)
Marra, Elena (158)
Ugo, Marone (159)
Zeppa, Pio (41)
Marra, Laura (40) (42)
Cinca, Sabin (161)
Xu, Haiying (166)
Fan, Jinshui (166)
Cope, Leslie (166)
Imai, Naoko (167)
Pan, Linda (168)
Park, Andrew (168)
Daniel, Speiser (170) (171)
Hirsh, Vera (172)

Affiliations

Organisations

  1. (1) The University of Texas MD Anderson Cancer Center, grid.240145.6
  2. (2) Fondazione IRCCS Istituto Nazionale dei Tumori, grid.417893.0
  3. (3) IRCCS Istituto Nazionale Tumori de “Fondazione G. Pascale”, Naples, Italy
  4. (4) Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Catanzaro “Magna Graecia”, Catanzaro, Italy
  5. (5) Takis s.r.l., Rome, Italy
  6. (6) Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale per lo Studio e la Cura Tumori Fondazione “G. Pascale”, Napoli, Italy
  7. (7) IRCCS Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples, Italy
  8. (8) Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori Fondazione “G. Pascale”, Napoli, Italy
  9. (9) The Ohio State University, grid.261331.4
  10. (10) Sapienza University of Rome, grid.7841.a
  11. (11) University of Chicago, grid.170205.1
  12. (12) Department of Pathology and Department of Medicine-Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA
  13. (13) Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
  14. (14) New York University, grid.137628.9
  15. (15) Cornell University, grid.5386.8
  16. (16) The University of Texas Southwestern Medical Center, grid.267313.2
  17. (17) Universitaets Spital, Zurich, Switzerland
  18. (18) University Hospital of Zurich, grid.412004.3
  19. (19) University of Zurich, grid.7400.3
  20. (20) Vanderbilt University Medical Center, grid.412807.8
  21. (21) Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA
  22. (22) University of Pittsburgh Cancer Institute, grid.478063.e
  23. (23) University of Pittsburgh, grid.21925.3d
  24. (24) University of Pittsburgh Medical Center, grid.412689.0
  25. (25) Biologics Discovery California, Bristol-Myers Squibb, 94063, Redwood City, CA, USA
  26. (26) National Institutes of Health Clinical Center, grid.410305.3
  27. (27) Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, MD, USA
  28. (28) University of Bern, grid.5734.5
  29. (29) Centre de Recherche des Cordeliers, grid.417925.c
  30. (30) Hôpital Européen Georges-Pompidou, grid.414093.b
  31. (31) Agencia Española de Medicamentos y Productos Sanitarios, grid.443875.9
  32. (32) Hospital Universitario Puerta de Hierro Majadahonda, grid.73221.35
  33. (33) Bocconi University, grid.7945.f
  34. (34) University of Eastern Piedmont Amadeo Avogadro, grid.16563.37
  35. (35) Karolinska Institute, grid.4714.6
  36. (36) Sidra Medical and Research Center, grid.467063.0
  37. (37) German Cancer Research Center, grid.7497.d
  38. (38) Unit of Pathology, Istituto Nazionale per lo Studio e la cura dei tumori “Fondazione G. Pascale” IRCCS, Naples, Italy
  39. (39) Pathology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione “G. Pascale”, Napoli, Italy
  40. (40) Pathology Unit, Istituto Nazionale Tumori de Fondazione “G. Pascale”, Napoli, Italy
  41. (41) University of Salerno, grid.11780.3f
  42. (42) Pathology Unit, Istituto Nazionale Tumori Fondazione “G. Pascale”, Napoli, Italy
  43. (43) Molecular Immunology and Immuneregulation, Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale”, Napoli, Italy
  44. (44) University of Naples Federico II, grid.4691.a
  45. (45) Memorial Sloan Kettering Cancer Center, grid.51462.34
  46. (46) Gustave Roussy and Paris-Sud University, Villejuif Paris-Sud, France
  47. (47) Institut Gustave Roussy, grid.14925.3b
  48. (48) University of Paris-Sud, grid.5842.b
  49. (49) Royal Marsden Hospital, grid.424926.f
  50. (50) Antoni van Leeuwenhoek Hospital, grid.430814.a
  51. (51) Ronald Reagan UCLA Medical Center, grid.413083.d
  52. (52) University of California, Los Angeles, grid.19006.3e
  53. (53) University Health Network, grid.231844.8
  54. (54) Angeles Clinic and Research Institute, grid.488730.0
  55. (55) Divisione chirurgia dermatoncologica, Europeo di Oncologia, Milan, Italy
  56. (56) University of Manchester, grid.5379.8
  57. (57) Vanderbilt University, grid.152326.1
  58. (58) Massachusetts General Hospital, grid.32224.35
  59. (59) Roche (United States), grid.418158.1
  60. (60) Kiel University, grid.9764.c
  61. (61) Peter MacCallum Cancer Centre, grid.1055.1
  62. (62) Yale New Haven Hospital, grid.417307.6
  63. (63) Georgetown University, grid.213910.8
  64. (64) Bristol-Myers Squibb (United States), grid.419971.3
  65. (65) Melanoma Institute Australia, grid.419690.3
  66. (66) National Institute of Oncology, grid.419617.c
  67. (67) Azienda Ospedaliera Universitaria Senese, grid.411477.0
  68. (68) Ospedale Papa Giovanni XXIII, grid.460094.f
  69. (69) Russian Cancer Research Center NN Blokhin, grid.466904.9
  70. (70) Department of Chemotherapy, Moscow City Oncology Hospital 62, Krasnogorsk, Russia
  71. (71) Centre Hospitalier Lyon Sud, grid.411430.3
  72. (72) Hospital Universitario Virgen Macarena, grid.411375.5
  73. (73) Gallipoli Medical Research Foundation, grid.479739.7
  74. (74) Princess Alexandra Hospital, grid.412744.0
  75. (75) Hôpital Saint-André, grid.414339.8
  76. (76) University of Tübingen, grid.10392.39
  77. (77) University of Nantes, grid.4817.a
  78. (78) Dana-Farber Cancer Institute, grid.65499.37
  79. (79) Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA
  80. (80) University of Michigan, grid.214458.e
  81. (81) Drug Development Unit, Sarah Cannon Research Institute/Tennessee Oncology PLLC, Nashville, TN, USA
  82. (82) University of Connecticut Health Center, grid.208078.5
  83. (83) Department of Medicine-Section of Hematology/Oncology, University of Chicago, Chicago, USA
  84. (84) MSD (United States), grid.417993.1
  85. (85) Incyte (United States), grid.417921.8
  86. (86) University of Pennsylvania, grid.25879.31
  87. (87) University of Sydney, grid.1013.3
  88. (88) University Hospital of Lausanne, grid.8515.9
  89. (89) West Cancer Center, grid.488536.4
  90. (90) University of Utah, grid.223827.e
  91. (91) Olivia Newton-John Cancer Center, Heidelberg, Australia
  92. (92) University Hospital of Geneva, grid.150338.c
  93. (93) Hospital Clinic of Barcelona, grid.410458.c
  94. (94) Temple University Health System, grid.412530.1
  95. (95) Amgen (United States), grid.417886.4
  96. (96) Cabrini Health, Melbourne, VIC, Australia
  97. (97) Hôpital Claude Huriez, grid.413875.c
  98. (98) University Hospital Heidelberg, grid.5253.1
  99. (99) Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland
  100. (100) Chris O’Brien Lifehouse, grid.419783.0
  101. (101) Chris O’Brien Lifehouse, The Melanoma Institute Australia and Royal Prince Alfred Hospital, Camperdown, Australia
  102. (102) Royal Prince Alfred Hospital, grid.413249.9
  103. (103) Wojewódzki Szpital Specjalistyczny im. M., Lodz, Poland
  104. (104) Hôpital Saint-Louis, grid.413328.f
  105. (105) University of Gothenburg, grid.8761.8
  106. (106) Instituto Alexander Fleming, grid.488972.8
  107. (107) Ospedale San Martino, grid.410345.7
  108. (108) University Medical Center of the Johannes Gutenberg University Mainz, grid.410607.4
  109. (109) Sunnybrook Health Science Centre, grid.413104.3
  110. (110) Hospital General Universitario De Valencia, grid.106023.6
  111. (111) Onkologikoa, grid.477678.d
  112. (112) Rambam Health Care Campus, grid.413731.3
  113. (113) Moffitt Cancer Center, grid.468198.a
  114. (114) Aix-Marseille University, grid.5399.6
  115. (115) Hospital General Universitario Gregorio Marañón, grid.410526.4
  116. (116) Aarhus University Hospital, grid.154185.c, Central Denmark Region
  117. (117) Department of Medical Oncology, Coffs Harbour Health Campus, Coffs Harbour, NSW, Australia
  118. (118) Cliniques Universitaires Saint-Luc, grid.48769.34
  119. (119) Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research, Weill Cornell Medical College, New York, NY, USA
  120. (120) Istituto Tumori “Giovanni Paolo II, Bari, Italy
  121. (121) Istituto Tumori “Giovanni Paolo II” I.R.R.C.S., Istituto di ricovero e cura a carattere scientifico, Bari, Italy
  122. (122) University of Bari Aldo Moro, grid.7644.1
  123. (123) Heidelberg University, grid.7700.0
  124. (124) Necker-Enfants Malades Hospital, grid.412134.1
  125. (125) Institut Cochin, grid.462098.1
  126. (126) University of Virginia, grid.27755.32
  127. (127) Universita della Svizzera Italiana, grid.29078.34
  128. (128) Universitätsklinikum Tübingen, grid.411544.1
  129. (129) Stanford University, grid.168010.e
  130. (130) Hospices Civils de Lyon, grid.413852.9
  131. (131) French Institute of Health and Medical Research, grid.7429.8
  132. (132) Paris Descartes University, grid.10992.33
  133. (133) Sorbonne University, grid.462844.8
  134. (134) Yale University, grid.47100.32
  135. (135) Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, INT “G. Pascale”, Napoli, Italy
  136. (136) Hôpital Saint-Antoine, grid.412370.3
  137. (137) National Cancer Center, grid.410914.9
  138. (138) Tulane University, grid.265219.b
  139. (139) Harvard University, grid.38142.3c
  140. (140) Centre Hospitalier Universitaire de Besançon, grid.411158.8
  141. (141) University of Franche-Comté, grid.7459.f
  142. (142) EA3181, SFR4234, Service de Dermatologie, Université de Franche Comté, Centre Hospitalier Universitaire (CHU), Besançon, France
  143. (143) Institute of Genetics and Biophysics, grid.419869.b
  144. (144) Department of Experimental Oncology, Istituto Nazionale Tumori Fondazione “G. Pascale”, Naples, Italy
  145. (145) University Parthenope, Naples, Italy
  146. (146) University ‘Parthenope’, Naples, Italy
  147. (147) Carol Davila University of Medicine and Pharmacy, grid.8194.4
  148. (148) Tel Aviv University, grid.12136.37
  149. (149) Laboratory of Cancer Genetics and Translational Oncology, S. Croce & amp, Carle Teaching Hospital, Cuneo, Italy
  150. (150) Dundee Cancer Center, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, UK
  151. (151) Imperial College London, grid.7445.2
  152. (152) Medical Oncology, Oncology Department, S. Croce & amp, Carle Teaching Hospital, Cuneo, Italy
  153. (153) Queen Mary University of London, grid.4868.2
  154. (154) PeptiPharma, Viale Città D’Europa 679, 00144, Rome, Italy
  155. (155) University of Rome Tor Vergata, grid.6530.0
  156. (156) Istituti Fisioterapici Ospitalieri, grid.417520.5
  157. (157) A.O.U. Maggiore della Carità, S.C. di Oncologia, Novara, Italy
  158. (158) A.O.U. Città della Salute e della Scienza, S.C. di Dermatologia, Torino, Italy
  159. (159) Department Melanoma, Division Surgery of Melanoma, National Cancer Institute “Fondazione Pascale”, Naples, Italy
  160. (160) University of Chieti-Pescara, grid.412451.7
  161. (161) Department of Carcinogenesis and Molecular Biology, “Alexandru Trestioreanu” Oncologic Institute, Bucharest, Romania
  162. (162) Istituto Dermopatico dell'Immacolata, grid.419457.a
  163. (163) Division Dermatology Villa Paola, Capranica, Italy
  164. (164) Mental Health Department, Hospital of Lauria, Rome, Italy
  165. (165) Dermatology and Oncology surgery of skin growths Department, Hospital of Caserta, Caserta, Italy
  166. (166) Johns Hopkins University, grid.21107.35
  167. (167) Icahn School of Medicine at Mount Sinai, grid.59734.3c
  168. (168) Ludwig Cancer Research, grid.1052.6
  169. (169) GSK Vaccines, Rixensart, Belgium
  170. (170) Princess Margaret Cancer Centre, grid.415224.4
  171. (171) University of Lausanne, grid.9851.5
  172. (172) McGill University, grid.14709.3b

Description

Table of contents

MELANOMA BRIDGE 2015

KEYNOTE SPEAKER PRESENTATIONS

Molecular and immuno-advances

K1 Immunologic and metabolic consequences of PI3K/AKT/mTOR activation in melanoma

Vashisht G. Y. Nanda, Weiyi Peng, Patrick Hwu, Michael A. Davies

K2 Non-mutational adaptive changes in melanoma cells exposed to BRAF and MEK inhibitors help the establishment of drug resistance

Gennaro Ciliberto, Luigi Fattore, Debora Malpicci, Luigi Aurisicchio, Paolo Antonio Ascierto, Carlo M. Croce, Rita Mancini

K3 Tumor-intrinsic beta-catenin signaling mediates tumor-immune avoidance

Stefani Spranger, Thomas F. Gajewski

K4 Intracellular tumor antigens as a source of targets of antibody-based immunotherapy of melanoma

Yangyang Wang, Soldano Ferrone

Combination therapies

K5 Harnessing radiotherapy to improve responses to immunotherapy in cancer

Claire Vanpouille-Box, Erik Wennerberg, Karsten A. Pilones, Silvia C. Formenti, Sandra Demaria

K6 Creating a T cell-inflamed tumor microenvironment overcomes resistance to checkpoint blockade

Haidong Tang, Yang Wang, Yang-Xin Fu

K7 Biomarkers for treatment decisions?

Reinhard Dummer

K8 Combining oncolytic therapies in the era of checkpoint inhibitors

Igor Puzanov

K9 Immune checkpoint blockade for melanoma: should we combine or sequence ipilimumab and PD-1 antibody therapy?

Michael A. Postow

News in immunotherapy

K10 An update on adjuvant and neoadjuvant therapy for melanom

Ahmad Tarhini

K11 Targeting multiple inhibitory receptors in melanoma

Joe-Marc Chauvin, Ornella Pagliano, Julien Fourcade, Zhaojun Sun, Hong Wang, Cindy Sanders, John M. Kirkwood, Tseng-hui Timothy Chen, Mark Maurer, Alan J. Korman, Hassane M. Zarour

K12 Improving adoptive immune therapy using genetically engineered T cells

David F. Stroncek

Tumor microenvironment and biomarkers

K13 Myeloid cells and tumor exosomes: a crosstalk for assessing immunosuppression?

Veronica Huber, Licia Rivoltini

K14 Update on the SITC biomarker taskforce: progress and challenges

Magdalena Thurin

World-wide immunoscore task force: an update

K15 The immunoscore in colorectal cancer highlights the importance of digital scoring systems in surgical pathology

Tilman Rau, Alessandro Lugli

K16 The immunoscore: toward an integrated immunomonitoring from the diagnosis to the follow up of cancer’s patients

Franck Pagès

Economic sustainability of melanoma treatments: regulatory, health technology assessment and market access issues

K17 Nivolumab, the regulatory experience in immunotherapy

Jorge Camarero, Arantxa Sancho

K18 Evidence to optimize access for immunotherapies

Claudio Jommi

ORAL PRESENTATIONS

Molecular and immuno-advances

O1 Ipilimumab treatment results in CD4 T cell activation that is concomitant with a reduction in Tregs and MDSCs

Yago Pico de Coaña, Maria Wolodarski, Yuya Yoshimoto, Giusy Gentilcore, Isabel Poschke, Giuseppe V. Masucci, Johan Hansson, Rolf Kiessling

O2 Evaluation of prognostic and therapeutic potential of COX-2 and PD-L1 in primary and metastatic melanoma

Giosuè Scognamiglio, Francesco Sabbatino, Federica Zito Marino, Anna Maria Anniciello, Monica Cantile, Margherita Cerrone, Stefania Scala, Crescenzo D’alterio, Angela Ianaro, Giuseppe Cirino, Paolo Antonio Ascierto, Giuseppina Liguori, Gerardo Botti

O3 Vemurafenib in patients with BRAFV600 mutation–positive metastatic melanoma: final overall survival results of the BRIM-3 study

Paul B. Chapman, Caroline Robert, James Larkin, John B. Haanen, Antoni Ribas, David Hogg, Omid Hamid, Paolo Antonio Ascierto, Alessandro Testori, Paul Lorigan, Reinhard Dummer, Jeffrey A. Sosman, Keith T. Flaherty, Huibin Yue, Shelley Coleman, Ivor Caro, Axel Hauschild, Grant A. McArthur

O4 Updated survival, response and safety data in a phase 1 dose-finding study (CA209-004) of concurrent nivolumab (NIVO) and ipilimumab (IPI) in advanced melanoma

Mario Sznol, Margaret K. Callahan, Harriet Kluger, Michael A. Postow, RuthAnn Gordan, Neil H. Segal, Naiyer A. Rizvi, Alexander Lesokhin, Michael B. Atkins, John M. Kirkwood, Matthew M. Burke, Amanda Ralabate, Angel Rivera, Stephanie A. Kronenberg, Blessing Agunwamba, Mary Ruisi, Christine Horak, Joel Jiang, Jedd Wolchok

Combination therapies

O5 Efficacy and correlative biomarker analysis of the coBRIM study comparing cobimetinib (COBI) + vemurafenib (VEM) vs placebo (PBO) + VEM in advanced BRAF-mutated melanoma patients (pts)

Paolo A. Ascierto, Grant A. McArthur, James Larkin, Gabriella Liszkay, Michele Maio, Mario Mandalà, Lev Demidov, Daniil Stoyakovskiy, Luc Thomas, Luis de la Cruz-Merino, Victoria Atkinson, Caroline Dutriaux, Claus Garbe, Matthew Wongchenko, Ilsung Chang, Daniel O. Koralek, Isabelle Rooney, Yibing Yan, Antoni Ribas, Brigitte Dréno

O6 Preliminary clinical safety, tolerability and activity results from a Phase Ib study of atezolizumab (anti-PDL1) combined with vemurafenib in BRAFV600-mutant metastatic melanoma

Ryan Sullivan, Omid Hamid, Manish Patel, Stephen Hodi, Rodabe Amaria, Peter Boasberg, Jeffrey Wallin, Xian He, Edward Cha, Nicole Richie, Marcus Ballinger, Patrick Hwu

O7 Preliminary safety and efficacy data from a phase 1/2 study of epacadostat (INCB024360) in combination with pembrolizumab in patients with advanced/metastatic melanoma

Thomas F. Gajewski, Omid Hamid, David C. Smith, Todd M. Bauer, Jeffrey S. Wasser, Jason J. Luke, Ani S. Balmanoukian, David R. Kaufman, Yufan Zhao, Janet Maleski, Lance Leopold, Tara C. Gangadhar

O8 Primary analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma

Reinhard Dummer, Georgina V. Long, Antoni Ribas, Igor Puzanov, Olivier Michielin, Ari VanderWalde, Robert H.I. Andtbacka, Jonathan Cebon, Eugenio Fernandez, Josep Malvehy, Anthony J. Olszanski, Thomas F. Gajewski, John M. Kirkwood, Christine Gause, Lisa Chen, David R. Kaufman, Jeffrey Chou, F. Stephen Hodi

News in immunotherapy

O9 Two-year survival and safety update in patients (pts) with treatment-naïve advanced melanoma (MEL) receiving nivolumab (NIVO) or dacarbazine (DTIC) in CheckMate 066

Victoria Atkinson, Paolo A. Ascierto, Georgina V. Long, Benjamin Brady, Caroline Dutriaux, Michele Maio, Laurent Mortier, Jessica C. Hassel, Piotr Rutkowski, Catriona McNeil, Ewa Kalinka-Warzocha, Celeste Lebbé, Lars Ny, Matias Chacon, Paola Queirolo, Carmen Loquai, Parneet Cheema, Alfonso Berrocal, Karmele Mujika Eizmendi, Luis De La Cruz-Merino, Gil Bar-Sela, Christine Horak, Joel Jiang, Helene Hardy, Caroline Robert

O10 Efficacy and safety of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL) who were treated beyond progression in CheckMate 066/067

Georgina V. Long, Jeffrey S. Weber, James Larkin, Victoria Atkinson, Jean-Jacques Grob, Reinhard Dummer, Caroline Robert, Ivan Marquez-Rodas, Catriona McNeil, Henrik Schmidt, Karen Briscoe, Jean-François Baurain, F. Stephen Hodi, Jedd D. Wolchok

Tumor microenvironment and biomarkers

O11 New biomarkers for response/resistance to BRAF inhibitor therapy in metastatic melanoma

Rosamaria Pinto, Simona De Summa, Vito Michele Garrisi, Sabino Strippoli, Amalia Azzariti, Gabriella Guida, Michele Guida, Stefania Tommasi

O12 Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma and response to ipilimumab

Nicolas Jacquelot, David Enot, Caroline Flament, Jonathan M. Pitt, Nadège Vimond, Carolin Blattner, Takahiro Yamazaki, Maria-Paula Roberti, Marie Vetizou, Romain Daillere, Vichnou Poirier-Colame, Michaëla Semeraro, Anne Caignard, Craig L Slingluff Jr, Federica Sallusto, Sylvie Rusakiewicz, Benjamin Weide, Aurélien Marabelle, Holbrook Kohrt, Stéphane Dalle, Andréa Cavalcanti, Guido Kroemer, Anna Maria Di Giacomo, Michaele Maio, Phillip Wong, Jianda Yuan, Jedd Wolchok, Viktor Umansky, Alexander Eggermont, Laurence Zitvogel

O13 Serum levels of PD1- and CD28-positive exosomes before Ipilimumab correlate with therapeutic response in metastatic melanoma patients

Passarelli Anna, Tucci Marco, Stucci Stefania, Mannavola Francesco, Capone Mariaelena, Madonna Gabriele, Ascierto Paolo Antonio, Silvestris Franco

O14 Immunological prognostic factors in stage III melanomas

María Paula Roberti, Nicolas Jacquelot, David P Enot, Sylvie Rusakiewicz, Michaela Semeraro, Sarah Jégou, Camila Flores, Lieping Chen, Byoung S. Kwon, Ana Carrizossa Anderson, Caroline Robert, Christophe Borg, Benjamin Weide, François Aubin, Stéphane Dalle, Michele Maio, Jedd D. Wolchok, Holbrook Kohrt, Maha Ayyoub, Guido Kroemer, Aurélien Marabelle, Andréa Cavalcanti, Alexander Eggermont, Laurence Zitvogel

POSTER PRESENTATIONS

Molecular and immuno-advances

P1 Human melanoma cells resistant to B-RAF and MEK inhibition exhibit mesenchymal-like features

Anna Lisa De Presbiteris, Fabiola Gilda Cordaro, Rosa Camerlingo, Federica Fratangelo, Nicola Mozzillo, Giuseppe Pirozzi, Eduardo J. Patriarca, Paolo A. Ascierto, Emilia Caputo

P2 Anti-proliferative and pro-apoptotic effect of ABT888 on melanoma cell lines and its potential role in the treatment of melanoma resistant to B-RAF inhibitors

Federica Fratangelo, Rosa Camerlingo, Emilia Caputo, Maria Letizia Motti, Rosaria Falcone, Roberta Miceli, Mariaelena Capone, Gabriele Madonna, Domenico Mallardo, Maria Vincenza Carriero, Giuseppe Pirozzi and Paolo Antonio Ascierto

P3 Involvement of the L-cysteine/CSE/H2S pathway in human melanoma progression

Elisabetta Panza, Paola De Cicco, Chiara Armogida, Giuseppe Ercolano, Rosa Camerlingo, Giuseppe Pirozzi, Giosuè Scognamiglio, Gerardo Botti, Giuseppe Cirino, Angela Ianaro

P4 Cancer stem cell antigen revealing pattern of antibody variable region genes were defined by immunoglobulin repertoire analysis in patients with malignant melanoma

Beatrix Kotlan, Gabriella Liszkay, Miri Blank, Timea Balatoni, Judit Olasz, Emil Farkas, Andras Szollar, Akos Savolt, Maria Godeny, Orsolya Csuka, Szabolcs Horvath, Klara Eles, Yehuda Shoenfeld and Miklos Kasler

P5 Upregulation of Neuregulin-1 expression is a hallmark of adaptive response to BRAF/MEK inhibitors in melanoma

Debora Malpicci, Luigi Fattore, Susan Costantini, Francesca Capone, Paolo Antonio Ascierto, Rita Mancini, Gennaro Ciliberto

P6 HuR positively regulates migration of HTB63 melanoma cells

Farnaz Moradi, Pontus Berglund, Karin Leandersson, Rickard Linnskog, Tommy Andersson, Chandra Prakash Prasad

P7 Prolyl 4- (C-P4H) hydroxylases have opposing effects in malignant melanoma: implication in prognosis and therapy

Cristiana Lo Nigro, Laura Lattanzio, Hexiao Wang, Charlotte Proby, Nelofer Syed, Marcella Occelli, Carolina Cauchi, Marco Merlano, Catherine Harwood, Alastair Thompson, Tim Crook

P8 Urokinase receptor antagonists: novel agents for the treatment of melanoma

Maria Letizia Motti, Katia Bifulco, Vincenzo Ingangi, Michele Minopoli, Concetta Ragone, Federica Fratangelo, Antonello Pessi, Gennaro Ciliberto, Paolo Antonio Ascierto, Maria Vincenza Carriero

P9 Exosomes released by melanoma cell lines enhance chemotaxis of primary tumor cells

Francesco Mannavola, Stella D’Oronzo, Claudia Felici, Marco Tucci, Antonio Doronzo, Franco Silvestris

P10 New insights in mitochondrial metabolic reprogramming in melanoma

Anna Ferretta, Gabriella Guida, Stefania Guida, Imma Maida, Tiziana Cocco, Sabino Strippoli, Stefania Tommasi, Amalia Azzariti, Michele Guida

P11 Lenalidomide restrains the proliferation in melanoma cells through a negative regulation of their cell cycle

Stella D’Oronzo, Anna Passarelli, Claudia Felici, Marco Tucci, Davide Quaresmini, Franco Silvestris

Combination therapies

P12 Chemoimmunotherapy elicits polyfunctional anti-tumor CD8 + T cells depending on the activation of an AKT pathway sustained by ICOS

Ornella Franzese, Belinda Palermo, Cosmo Di Donna, Isabella Sperduti, MariaLaura Foddai, Helena Stabile, Angela Gismondi, Angela Santoni, Paola Nisticò

P13 Favourable toxicity profile of combined BRAF and MEK inhibitors in metastatic melanoma patients

Andrea P. Sponghini, Francesca Platini, Elena Marra, David Rondonotti, Oscar Alabiso, Maria T. Fierro, Paola Savoia, Florian Stratica, Pietro Quaglino

P14 Electrothermal bipolar vessel sealing system dissection reduces seroma output or time to drain removal following axillary and ilio-inguinal node dissection in melanoma patients: a pilot study

Di Monta Gianluca, Caracò Corrado, Di Marzo Massimiliano, Marone Ugo, Di Cecilia Maria Luisa, Mozzillo Nicola

News in immunotherapy

P15 Clinical and immunological response to ipilimumab in a metastatic melanoma patient with HIV infection

Francesco Sabbatino, Celeste Fusciello1, Antonio Marra, Rosario Guarrasi, Carlo Baldi, Rosa Russo, Di Giulio Giovanni, Vincenzo Faiola, Pio Zeppa, Stefano Pepe

P16 Immunotherapy and hypophysitis: a case report

Elisabetta Gambale, Consiglia Carella, Alessandra Di Paolo, Michele De Tursi

Tumor microenvironment and biomarkers

P17 New immuno- histochemical markers for the differential diagnosis of atypical melanocytic lesions with uncertain malignant potential

Laura Marra, Giosuè Scognamiglio, Monica Cantile, Margherita Cerrone, Fara De Murtas, Valeria Sorrentino, Anna Maria Anniciello, Gerardo Botti

P18 Utility of simultaneous measurement of three serum tumor markers in melanoma patients

Angela Sandru, Silviu Voinea, Eugenia Panaitescu, Madalina Bolovan, Adina Stanciu, Sabin Cinca

P19 The significance of various cut-off levels of melanoma inhibitory activity in evaluation of cutaneous melanoma patients

Angela Sandru, Silviu Voinea, Eugenia Panaitescu, Madalina Bolovan, Adina Stanciu, Sabin Cinca

P20 The long noncoding RNA HOTAIR is associated to metastatic progression of melanoma and it can be identified in the blood of patients with advanced disease

Chiara Botti, Giosuè Scognamiglio, Laura Marra, Gabriella Aquino, Rosaria Falcone, Annamaria Anniciello, Paolo Antonio Ascierto, Gerardo Botti, Monica Cantile

Other

P21 The effect of Sentinel Lymph Node Biopsy in melanoma mortality: timing of dissection

Cristina Fortes, Simona Mastroeni, Alessio Caggiati, Francesca Passarelli, Alba Zappalà, Maria Capuano, Riccardo Bono, Maurizio Nudo, Claudia Marino, Paola Michelozzi

P22 Epidemiological survey on related psychopathology in melanoma

Valeria De Biasio, Vincenzo C. Battarra

IMMUNOTHERAPY BRIDGE

KEYNOTE SPEAKER PRESENTATIONS

Immunotherapy beyond melanoma

K19 Predictor of response to radiation and immunotherapy

Silvia Formenti

K20 Response and resistance to PD-1 pathway blockade: clues from the tumor microenvironment

Maria Libera Ascierto, Tracee L. McMiller, Alan E. Berger, Ludmila Danilova, Robert A. Anders, George J. Netto, Haiying Xu, Theresa S. Pritchard, Jinshui Fan, Chris Cheadle, Leslie Cope, Charles G. Drake, Drew M. Pardoll, Janis M. Taube and Suzanne L. Topalian

K21 Combination immunotherapy with autologous stem cell transplantation, protein immunization, and PBMC reinfusion in myeloma patients

Sacha Gnjatic, Sarah Nataraj, Naoko Imai, Adeeb Rahman, Achim A. Jungbluth, Linda Pan, Ralph Venhaus, Andrew Park, Frédéric F. Lehmann, Nikoletta Lendvai, Adam D. Cohen, and Hearn J. Cho

K22 Anti-cancer immunity despite T cell “exhaustion”

Speiser Daniel

Immunotherapy in oncology (I-O): data from clinical trial

K23 The Checkpoint Inhibitors for the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)

Vera Hirsh

Research Categories

Main Subject Area

Fields of Research

Links & Metrics

Dimensions Citation Indicators

Times Cited: 8

Field Citation Ratio (FCR): 2.08

Relative Citation ratio (RCR): 0.26

Open Access Info

Pure Gold